Clinical Trials on Pancreatic G-cell Carcinoma

Total 13318 results

Northwestern University
GlaxoSmithKline; National Comprehensive Cancer Network; Robert H. Lurie Cancer...

Completed

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Recurrent Islet Cell Carcinoma | Pancreatic Alpha Cell Carcinoma | Pancreatic Beta Islet Cell Carcinoma | Pancreatic Delta Cell Carcinoma | Pancreatic G-cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Pancreatic Carcinoma | Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy (S1115)

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Pancreatic Acinar Cell Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Pulmonary Carcinoid Tumor

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Pancreatic Acinar Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Lung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Paraganglioma | Pancreatic Polypeptide Tumor | Pancreatic Glucagonoma | Pancreatic Insulinoma | Recurrent Merkel Cell Carcinoma | Somatostatin-Producing Neuroendocrine Tumor | Stage IV Merkel Cell Carcinoma | Recurrent Digestive... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Regional Gastrointestinal Carcinoid Tumor | Pulmonary Carcinoid Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Pancreatic Cancer | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinomas of Pancreas | Islet Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Pancreatic Acinar Cell Carcinoma | Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Pancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Pancreatic Acinar Cell Carcinoma | Locally Advanced Pancreatic Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid Tumor

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Unresectable Pancreatic Neuroendocrine Carcinoma

United States
Shaheen Shagufta
National Cancer Institute (NCI)

Completed

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Neuroendocrine Tumor | Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
Cancer Research UK

Active, not recruiting

A CR-UK Phase I Trial of LY3143921

a. Colorectal Cancer | b. High Grade Serous Ovarian Cancer | c. Non Small-cell Lung Cancer (Squamous Cell Variant) | d. Squamous Carcinoma of the Oesophagus | e. Squamous Carcinoma of the Head and Neck (HPV Negative) | f. Urothelial Cancer | g. Breast Cancer (Triple Negative Type) | h. Pancreatic...

United Kingdom
National Cancer Institute (NCI)

Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Endometrial Serous Adenocarcinoma | Lung Carcinoid Tumor | Metastatic... and other conditions

United States, Canada
H. Lee Moffitt Cancer Center and Research Institute
Pharmacyclics LLC.

Completed

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Carcinoid Tumors | Pancreatic NET

United States
National Cancer Institute (NCI)

Active, not recruiting

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Metastatic Pancreatic Carcinoma | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | B-Cell Non-Hodgkin Lymphoma | Metastatic Pancreatic Carcinoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Refractory T-Cell... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Pancreatic Adenocarcinoma | Metastatic... and other conditions

United States
Roswell Park Cancer Institute
Ipsen

Active, not recruiting

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Unresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Gastrointestinal Carcinoid Tumor | Islet Cell Carcinoma
National Cancer Institute (NCI)
AstraZeneca

Active, not recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Advanced Malignant Solid Neoplasm | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IIIA Lung Non-Small... and other conditions

United States, Canada
National Cancer Institute (NCI)

Recruiting

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Pancreatic Acinar Cell Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Withdrawn

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Islet Cell Carcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Liver Metastases | Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma

United States
James Cleary, MD, PhD
Lustgarten Foundation; Arcus Biosciences, Inc.

Recruiting

Switch Maintenance in Pancreatic

Pancreatic Cancer | Adenocarcinoma of the Pancreas | Squamous Cell Carcinoma of Pancreas | Adenosquamous Carcinoma of the Pancreas

United States
University of Michigan Rogel Cancer Center

Recruiting

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Pancreatic Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Carcinoma | Adenosquamous Carcinoma | Gastrointestinal Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Carcinoma | Neuroendocrine Prostate Carcinoma

United States
Ochsner Health System

Unknown

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Neuroendocrine Tumor | Neuroendocrine Carcinoma | Carcinoid Tumor | Neuroendocrine Cancer | Carcinoid | Islet Cell Tumor | Neuroendocrine | Apudoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France; Advanced Accelerator Applications

Recruiting

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM)

Pancreatic Neuroendocrine Carcinoma

France
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Breast Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Other Solid Tumors | Pancreatic Ductal Carcinoma

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Other Solid Tumors | Pancreatic Ductal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Locally Advanced Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Pancreatic Vipoma | Pancreatic Gastrinoma | Advanced Pancreatic Neuroendocrine Tumor

United States, Canada
Yale University
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage I Pancreatic Cancer

United States
Pfizer

Terminated

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

Carcinoma, Islet Cell | Carcinoma, Pancreas

United States, Canada, Belgium, Spain, Australia, Germany, Korea, Republic of, Taiwan, United Kingdom, France, Italy
Laser Tissue Welding, Inc.
National Cancer Institute (NCI); CHI St. Luke's Health, Texas

Completed

Laser Tissue Welding - Distal Pancreatectomy Sealing Study (LTW)

Pancreatic Neoplasms | Pancreatic Adenocarcinoma | Pancreatic Cyst | Pancreatic Neuroendocrine Tumor | Pancreatic Polypeptide Tumor | Pancreatic Pseudocyst | Pancreatic Glucagonoma | Pancreas Injury | Pancreatic Cystadenoma | Pancreatic Tumor, Benign | Pancreas; Insulinoma | Pancreatic Teratoma | Pancreatic Vipoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Assessment of What Patients and Healthcare Providers Value

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Pancreatic Neuroendocrine Carcinoma

United States
Translational Oncology Research International

Completed

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Terminated

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Pancreatic Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage... and other conditions

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Terminated

Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IIB Pancreatic Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital; Amgen; H. Lee Moffitt...

Completed

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Roswell Park Cancer Institute
NeuroEndocrine Tumor Research Foundation (NETRF)

Recruiting

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Lung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid Tumor

United States

Clinical Trials on Pancreatic G-cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations